Livestream

Do periurethral injections with Bulkamid (polyacrylamide hydrogel) for the treatment of stress urinary incontinence truly fail by 24 months? Failure rate, time to failure, and risk factors for failure in a large retrospective cohort

Thursday, October 5, 2023

3:48 PM – 3:52 PM US PST

Location: B113-116

Presenting Author(s)

Alykhan Rajwani, MD, FRCSC

Obstetrician and Gynecologist
Department of Obstetrics and Gynecology, Surrey Memorial Hospital
Surrey, British Columbia, Canada

PDF

Co-Author(s)

CY

Camille Yearwood, PharmD

MD Student
University of Alberta School of Medicine and Dentistry
Edmonton, Alberta, Canada
MS

May Sanaee, MD FRCSC MHScEd (she/her/hers)

Clinical Associate Professor
University of Alberta
EDMONTON, Alberta, Canada
PG

Paul Groves, MD FRCSC

Urogynecologist
University of Alberta
Edmonton, Alberta, Canada
EK

Erin Kelly, BSC MD (she/her/hers)

Clinical Assistant Professor
University of Alberta
Edmonton, Alberta, Canada

Disclosure(s):

Alykhan Rajwani, MD, FRCSC: SEARCHLIGHT PHARMA INC: Researcher (Terminated)

Camille Yearwood, PharmD: No financial relationships to disclose

May Sanaee, MD FRCSC MHScEd: ABBVIE CANADA: Advisory Board (Ongoing); LUPIN PHARMA CANADA LTD: Advisory Board (Ongoing)

Paul Groves, MD FRCSC: No financial relationships to disclose

Erin Kelly, BSC MD: Searchlight Pharma: grant of %5000.00 CAD (Ongoing)

Polyacrylamide hydrogel (Bulkamid) is a synthetic bulking agent that has been found to have reasonable effectiveness for treating stress urinary incontinence (SUI). Despite lower overall success rates compared to slings, it is an attractive option for women who cannot tolerate an invasive procedure, or women who wish to minimize the risks of an incontinence procedure. Several studies have looked into the effectiveness of Bulkamid, however there is less data available on the failure rate and risk factors for failure. Knowing the risk of failure and time to failure of the Bulkamid procedure, as well as the risk factors for failure, would potentially enable surgeons to better select, and counsel patients regarding Bulkamid periurethral injections for the treatment of their SUI.